Advertisement

Glenmark launches COVID-19 drug after DCGI nod

Follow The Hawk on Google News+ Follow

Advertisement

New Delhi: Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.

The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).

Advertisement

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

'This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system,' Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added. PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST